Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire
<h4>Objectives</h4> <p>o finalise and validate a disease-specific patient-reported outcome (PRO) measure: the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire. Using a 35-item candidate questionnaire developed following 50 qualitative interviews in the U...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2018
|
| _version_ | 1797091908894326784 |
|---|---|
| author | Robson, J Dawson, J Doll, H Cronholm, P Milman, N Kellom, K Ashdown, S Easley, E Gebhart, D Lanier, G Mills, J Peck, J Luqmani, R Shea, J Tomasson, G Merkel, P |
| author_facet | Robson, J Dawson, J Doll, H Cronholm, P Milman, N Kellom, K Ashdown, S Easley, E Gebhart, D Lanier, G Mills, J Peck, J Luqmani, R Shea, J Tomasson, G Merkel, P |
| author_sort | Robson, J |
| collection | OXFORD |
| description | <h4>Objectives</h4> <p>o finalise and validate a disease-specific patient-reported outcome (PRO) measure: the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire. Using a 35-item candidate questionnaire developed following 50 qualitative interviews in the UK, USA and Canada, a longitudinal survey was conducted to determine the final scale structure and validate the AAV-PRO.</p> <h4>Methods</h4> <p>Participants were recruited via Vasculitis UK and the Vasculitis Patient-Powered Research Network. The 35-item candidate questionnaire was completed at baseline and 3 months; UK participants completed the EuroQol-5D-5L (EQ-5D-5L), while US participants completed a test–retest exercise, 3–5 days after baseline. Scale structure was defined using exploratory factor analysis (EFA) and Rasch analysis. Convergent and known groups validity, test–retest reliability and longitudinal construct validity were assessed.</p> <h4>Results</h4> <p>here were 626 participants with AAV; >25% reporting ’active disease’. EFA and Rasch analysis supported a 29-item profile measure comprising six domains: ’organ-specific symptoms’, ’systemic symptoms’, ’treatment side effects’, ’social and emotional impact’, ’concerns about the future’ and ’physical function’. Mean domain scores were higher for participants with ’active disease’ versus ’remission’ (p<0.001). Construct validity was demonstrated by correlations between domain scores and the EQ-5D-5L (range r=−0.55 to 0.78), all p<0.0001. In participants reporting ’no change’ (n=97) during the test–retest, intraclass correlation coefficient values were high (range 0.89–0.96) for each domain.</p> <h4>Conclusions</h4> <p>he AAV-PRO, a new disease-specific PRO measure for AAV, has good face and construct validity, is reliable, feasible and discriminates among disease states.</p> |
| first_indexed | 2024-03-07T03:39:06Z |
| format | Journal article |
| id | oxford-uuid:bd469833-055b-45eb-828d-184e36b2efaa |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:39:06Z |
| publishDate | 2018 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:bd469833-055b-45eb-828d-184e36b2efaa2022-03-27T05:30:43ZValidation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaireJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bd469833-055b-45eb-828d-184e36b2efaaEnglishSymplectic Elements at OxfordBMJ Publishing Group2018Robson, JDawson, JDoll, HCronholm, PMilman, NKellom, KAshdown, SEasley, EGebhart, DLanier, GMills, JPeck, JLuqmani, RShea, JTomasson, GMerkel, P <h4>Objectives</h4> <p>o finalise and validate a disease-specific patient-reported outcome (PRO) measure: the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire. Using a 35-item candidate questionnaire developed following 50 qualitative interviews in the UK, USA and Canada, a longitudinal survey was conducted to determine the final scale structure and validate the AAV-PRO.</p> <h4>Methods</h4> <p>Participants were recruited via Vasculitis UK and the Vasculitis Patient-Powered Research Network. The 35-item candidate questionnaire was completed at baseline and 3 months; UK participants completed the EuroQol-5D-5L (EQ-5D-5L), while US participants completed a test–retest exercise, 3–5 days after baseline. Scale structure was defined using exploratory factor analysis (EFA) and Rasch analysis. Convergent and known groups validity, test–retest reliability and longitudinal construct validity were assessed.</p> <h4>Results</h4> <p>here were 626 participants with AAV; >25% reporting ’active disease’. EFA and Rasch analysis supported a 29-item profile measure comprising six domains: ’organ-specific symptoms’, ’systemic symptoms’, ’treatment side effects’, ’social and emotional impact’, ’concerns about the future’ and ’physical function’. Mean domain scores were higher for participants with ’active disease’ versus ’remission’ (p<0.001). Construct validity was demonstrated by correlations between domain scores and the EQ-5D-5L (range r=−0.55 to 0.78), all p<0.0001. In participants reporting ’no change’ (n=97) during the test–retest, intraclass correlation coefficient values were high (range 0.89–0.96) for each domain.</p> <h4>Conclusions</h4> <p>he AAV-PRO, a new disease-specific PRO measure for AAV, has good face and construct validity, is reliable, feasible and discriminates among disease states.</p> |
| spellingShingle | Robson, J Dawson, J Doll, H Cronholm, P Milman, N Kellom, K Ashdown, S Easley, E Gebhart, D Lanier, G Mills, J Peck, J Luqmani, R Shea, J Tomasson, G Merkel, P Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
| title | Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
| title_full | Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
| title_fullStr | Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
| title_full_unstemmed | Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
| title_short | Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
| title_sort | validation of the anca associated vasculitis patient reported outcomes aav pro questionnaire |
| work_keys_str_mv | AT robsonj validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT dawsonj validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT dollh validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT cronholmp validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT milmann validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT kellomk validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT ashdowns validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT easleye validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT gebhartd validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT lanierg validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT millsj validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT peckj validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT luqmanir validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT sheaj validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT tomassong validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire AT merkelp validationoftheancaassociatedvasculitispatientreportedoutcomesaavproquestionnaire |